IMpower010: Atezolizumab improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care
The phase III IMpower010 study evaluating Atezolizumab ( Tecentriq ), compared with best supportive care ( BSC ), has met its primary endpoint of disease-free survival ( DFS ) at the interim analysis. ...
read article